114/09/18 12:30 - 13:30

114/08/18 09:10-114/09/17 14:00

線上課程

時段	主題	講師	主持人
12:30~13:30	The Transforming Role of SGLT2 Inhibitors for Kidney Protection	徐盛邦 醫師 惠騰診所	羅文一 醫師 隆安診所

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have revolutionized the treatment landscape of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Initially developed as glucose-lowering agents, SGLT2i have demonstrated remarkable renoprotective benefits beyond glycemic control, making them a cornerstone therapy for kidney protection in diabetic and non-diabetic patients.
Renal Protection Beyond Glucose Control
SGLT2i exert multiple beneficial effects on the kidneys, primarily through reducing intraglomerular pressure and mitigating hyperfiltration, key drivers of CKD progression. By inhibiting glucose and sodium reabsorption in the proximal tubules, these agents restore tubuloglomerular feedback, leading to afferent arteriole constriction and a reduction in glomerular pressure. This mechanism translates into reduced albuminuria, slower decline in estimated glomerular filtration rate (eGFR), and delayed onset of end-stage kidney disease (ESKD).
Evidence from Landmark Clinical Trials
Major clinical trials, including CREDENCE, DAPA-CKD, and EMPA-KIDNEY, have confirmed the robust kidney benefits of SGLT2i. These studies demonstrated that canagliflozin, dapagliflozin, and empagliflozin significantly lower the risk of CKD progression, dialysis initiation, and cardiovascular events. Notably, these benefits extend to patients without diabetes, reinforcing the role of SGLT2i as a kidney-specific therapy rather than solely a glucose-lowering agent.
Cardiorenal Benefits and Mortality Reduction
Beyond kidney protection, SGLT2i have profound effects on heart failure and cardiovascular mortality. They reduce the risk of heart failure hospitalization and major adverse cardiovascular events (MACE), making them an essential component of cardiorenal-metabolic (CKM) management. This paradigm shift has positioned SGLT2i as first-line therapy in CKD guidelines, independent of diabetes status.
Expanding Indications and Future Directions
The evolving role of SGLT2i continues to expand, with ongoing research exploring their anti-inflammatory, antifibrotic, and metabolic benefits. Future studies will likely establish their role in non-diabetic kidney disease, acute kidney injury prevention, and combination therapy with other renoprotective agents such as mineralocorticoid receptor antagonists (MRAs) and GLP-1 receptor agonists. Conclusion
SGLT2 inhibitors have transformed the management of CKD, offering a powerful tool for kidney and cardiovascular protection. Their ability to delay dialysis, reduce mortality, and improve long-term renal outcomes underscores their role as a cornerstone therapy in nephrology and metabolic medicine. As we embrace this new era of renal protection, SGLT2i represent a paradigm shift towards holistic, multi-organ management in CKD.

線上研討會

會員常年會費繳清者免費，非會員100元。未於時間內繳費者，學會有權取消報名，並釋出名額。

-

台灣內科醫學會B類 1分
社團法人中華民國藥師公會全國聯合會
家醫計畫2.0時數1小時DKD 1小時
三高防治教育訓練課程(全人全社區計畫)1小時
臺北市糖尿病共同照護網
《實際學分數以各醫學會實際通過為主，包含審查中之各醫學會學分》